glp-1 receptor agonist pancreatitis risk meta-analysis RAs and Pancreatitis: No Significant Increase Found in | Yasir Elamin posted on the topic New data links GLP-1 agonists
Description
Design In the obesity trial, 338 participants (mean age 48 years, 48% women, mean BMI 37.3 kg/m 2 ) were randomised (2:1:1:1:1:2:2) to retatrutide 1 mg, 4 mg (titration), 4 mg (no titration), 8 mg (slow titration), 8 mg (fast titration), 12 mg or placebo over 48 weeks [45]
Excited, Eng tested exendin-4 in diabetic rodents: the results were astonishing exendin-4 lowered blood glucose to normal and kept it low for hours, even over a day in some cases ( [50] )
Strategic Implications If validated in prospective randomized trials, GLP-1 receptor agonists could: Represent an adjunctive strategy in obesity-associated asthma Expand the therapeutic footprint of GLP-1s beyond metabolic disease Influence treatment guidelines in high-BMI asthma populations Given the rapid adoption of GLP-1 therapies globally, further investigation into respiratory benefits could have significant clinical and commercial implications
New developments, such as dual and triple agonists that target the glucagon, GLP-1, and GIP receptors, promise better results
6 Care should also be taken with alogliptin
